By Graham Wylie, Chair and Chief Executive, Medical Research Network
Welcome to the second instalment of our five-part series exploring the true return on investment of Home Trial Support (HTS). In our previous post, we looked at how decentralised nursing addresses the root causes of site fragility. If you missed Part 1, you can catch up here [Link].
In this post, we examine values three and four from our list: putting the patient first and researching therapies directly in the home environment.
The 2020 Perspective
In the original 2020 series, patient-centric sponsors were increasingly treating the trial participant as their ultimate customer. At the same time, regulatory authorities were beginning to encourage patient-relevant endpoints – shifting focus towards whether a patient can manage daily functional tasks, such as feeding themselves, rather than relying solely on clinical surrogates like grip dynamometer scores.
Sponsors holding this view wanted to repay participants for volunteering by easing the burden of taking part, and they were willing to invest in the patient relationship rather than looking purely at immediate line-item savings. Alongside this, another group of sponsors recognised that because their product would ultimately be administered at home once approved, testing it in the home environment from the outset delivered far more real-world-applicable evidence while limiting the therapy’s intrusion into the patient’s everyday life.
Where It Stands Today
Values three and four have proven to be the most durable of the five, and they have aged exceptionally well.
MRN’s pharmaceutical customers increasingly view the patient as the ultimate customer, and regulatory bodies have fully aligned with this direction. Regulators are actively pushing towards the endpoints participants care about most. The progression from a Physician Global Assessment to a Patient Global Assessment – or measuring whether an individual can hold cutlery rather than squeeze a gauge – reflects this exact philosophy, and it is now routinely informing product labelling. Sponsors who embrace this mindset are committed to making participation easier, seeing clear long-term value in supporting the volunteer beyond basic cost considerations.
The fourth value takes that same patient-first logic straight into commercial reality. When a sponsor knows a therapy is destined for domestic administration once marketed, studying it in that setting from day one grounds the trial in real-world conditions. It expands the purpose of the treatment: not only treating the condition, but minimising the impact of the medical regimen itself on the individual’s daily routine. With far more advanced therapeutics designed for at-home administration today, the commercial and clinical significance of this value continues to grow.